Assessment of Cone-Beam Breast Computed Tomography for Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Prospective Study
Table 1
Baseline characteristics of patients.
Characteristics
pCR ()
Non-pCR ()
value
Side
Left
15 (41.7)
19 (42.2)
0.594
Right
21 (58.3)
26 (57.8)
Age (years)
0.003
Body mass index
0.806
Low
2 (5.6)
3 (0.6)
Normal
24 (66.7)
30 (66.7)
Obesity
8 (22.2)
10 (22.2)
Overweight
2 (5.6)
2 (0.5)
Menopausal status
0.447
Premenopausal
30 (83.3)
37 (82.2)
Postmenopausal
6 (16.7)
8 (17.8)
Family history
0.786
With
7 (19.4)
9 (20.0)
Without
29 (80.6)
36 (80.0)
Therapy
0.078
Doxorubicin
0 (0)
0 (10.3)
Paclitaxel without trastuzumab target
22 (61.1)
27 (51.7)
Paclitaxel with trastuzumab target
14 (38.9)
18 (37.9)
Tumor baseline size (mm)
32.4 (24.5, 48.1)
44.6 (29.2, 58.1)
0.067
Histologic type
0.246
Ductal carcinoma in situ
1 (2.8)
1 (2.2)
Invasive ductal carcinoma
34 (94.4)
43 (95.6)
Mixing invasive carcinoma
1 (2.8)
1 (2.2)
Hormone receptor
0.981
Positive negative
15 (41.7)
1832 (40.071.1)
Negative positive
21 (58.3)
2713 (6028.9.0)
HER2
0.951
Negative
6 (16.7)
7 (15.6)
Positive
30 (83.3)
38 (84.4)
Ki-67 receptor
0.197
Low
2 (5.6)
3 (6.7)
High
34 (94.4)
42 (93.3)
Complications
0.439
With
7 (19.4)
9 (20.0)
Without
29 (80.6)
36 (80.0)
Note: The data reveals numbers of patients in the pCR and non-pCR group with percentages in parentheses or . values marked asterisk present significant statistical value. pCR: Pathologic complete response; HER: Human epidermal growth factor receptor.
